Aequus Pharmaceuticals Inc. (TSXV: AQS)
Canada
· Delayed Price · Currency is CAD 0.0050
0.00 (0.00%)
Jan 13, 2025, 1:53 PM EST
Aequus Pharmaceuticals Income Statement
Financials in millions CAD. Fiscal year is January - December.
Millions CAD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 0.41 | 0.25 | 1.38 | 2.71 | 2.59 | 1.63 | Upgrade
|
| Revenue Growth (YoY) | -29.63% | -81.53% | -49.17% | 4.71% | 58.81% | 15.76% | Upgrade
|
| Cost of Revenue | 0.19 | 0.11 | 0.1 | 0.04 | - | - | Upgrade
|
| Gross Profit | 0.22 | 0.14 | 1.28 | 2.67 | 2.59 | 1.63 | Upgrade
|
| Selling, General & Admin | 2.71 | 2.66 | 3.69 | 3.98 | 3.32 | 3.86 | Upgrade
|
| Research & Development | - | 0.3 | 0.17 | 0.3 | 0.05 | 0.21 | Upgrade
|
| Operating Expenses | 2.71 | 2.96 | 3.86 | 4.28 | 3.37 | 4.07 | Upgrade
|
| Operating Income | -2.49 | -2.82 | -2.58 | -1.61 | -0.78 | -2.44 | Upgrade
|
| Interest Expense | -0.23 | -0.15 | -0.13 | -0.21 | -0.29 | -0.2 | Upgrade
|
| Interest & Investment Income | 0.01 | 0 | 0.02 | 0.01 | 0 | 0.01 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.01 | -0 | 0.04 | -0 | -0 | -0 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.04 | - | -0.57 | - | - | - | Upgrade
|
| EBT Excluding Unusual Items | -2.68 | -2.96 | -3.21 | -1.81 | -1.06 | -2.63 | Upgrade
|
| Asset Writedown | - | - | - | - | - | -0.48 | Upgrade
|
| Other Unusual Items | - | - | - | - | 0.02 | - | Upgrade
|
| Pretax Income | -2.68 | -2.96 | -3.21 | -1.81 | -1.05 | -3.11 | Upgrade
|
| Net Income | -2.68 | -2.96 | -3.21 | -1.81 | -1.05 | -3.11 | Upgrade
|
| Net Income to Common | -2.68 | -2.96 | -3.21 | -1.81 | -1.05 | -3.11 | Upgrade
|
| Shares Outstanding (Basic) | 133 | 133 | 133 | 129 | 93 | 80 | Upgrade
|
| Shares Outstanding (Diluted) | 133 | 133 | 133 | 129 | 93 | 80 | Upgrade
|
| Shares Change (YoY) | - | - | 2.94% | 38.28% | 15.86% | 6.33% | Upgrade
|
| EPS (Basic) | -0.02 | -0.02 | -0.02 | -0.01 | -0.01 | -0.04 | Upgrade
|
| EPS (Diluted) | -0.02 | -0.02 | -0.02 | -0.01 | -0.01 | -0.04 | Upgrade
|
| Free Cash Flow | -2.48 | -2.29 | -1.95 | -1.18 | -0.82 | -1.63 | Upgrade
|
| Free Cash Flow Per Share | -0.02 | -0.02 | -0.01 | -0.01 | -0.01 | -0.02 | Upgrade
|
| Gross Margin | 53.45% | 56.36% | 92.49% | 98.42% | 100.00% | 100.00% | Upgrade
|
| Operating Margin | -601.60% | -1106.45% | -187.17% | -59.22% | -30.08% | -149.54% | Upgrade
|
| Profit Margin | -647.62% | -1163.11% | -232.65% | -66.66% | -40.32% | -190.26% | Upgrade
|
| Free Cash Flow Margin | -599.91% | -899.97% | -141.51% | -43.33% | -31.52% | -99.96% | Upgrade
|
| EBITDA | -2.48 | -2.81 | -2.58 | -1.6 | -0.69 | -2.25 | Upgrade
|
| EBITDA Margin | - | - | -186.67% | -58.91% | -26.56% | -137.95% | Upgrade
|
| D&A For EBITDA | 0.01 | 0.01 | 0.01 | 0.01 | 0.09 | 0.19 | Upgrade
|
| EBIT | -2.49 | -2.82 | -2.58 | -1.61 | -0.78 | -2.44 | Upgrade
|
| EBIT Margin | - | - | -187.17% | -59.22% | -30.08% | -149.54% | Upgrade
|
| Revenue as Reported | 0.25 | 0.25 | 1.38 | 2.71 | 2.59 | - | Upgrade
|
| Advertising Expenses | - | 0.23 | 0.24 | 0.22 | 0.1 | 0.15 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.